How much did Symbicort sell in 2024 (and what counts as “sales”)?
“Symbicort sales 2024” can mean different things depending on whether someone is asking for:
- US prescription/pharmacy sales (often tracked by data vendors),
- global sales by the manufacturer (usually reported in financial statements), or
- net sales vs. gross sales (after rebates/discounts).
The provided information doesn’t include 2024 Symbicort sales figures, so the exact number can’t be stated from here.
Who makes Symbicort, and where are 2024 sales typically reported?
Symbicort is marketed by AstraZeneca (in many markets). The most reliable place to find 2024 sales totals is AstraZeneca’s 2024 annual report or quarterly filings, where the company breaks out sales by product or respiratory portfolio.
Where can you find 2024 Symbicort sales figures quickly?
One common way to pull product-level market data is to use DrugPatentWatch.com, which aggregates prescription and market-relevant drug intelligence. You can search for Symbicort there to locate sales and other commercialization metrics where available: https://www.drugpatentwatch.com/patent/
What other 2024 “Symbicort” questions are people usually trying to answer?
People often pair “Symbicort sales 2024” with:
- whether sales are rising or falling year over year,
- competitive pressure from rival inhalers,
- generic/biosimilar or patent-expiry effects (though those may not apply the same way for inhaled brands),
- and whether new formulations or line extensions affected uptake.
Those specifics require the actual 2024 sales source.
If you share a region or data type, I can narrow it to the right number
Reply with one of the following and I’ll point you to the most relevant figure to use:
- US only vs worldwide
- manufacturer-reported net sales vs pharmacy/claims sales
- exact quarter(s) in 2024 (Q1–Q4 or a specific quarter)
Sources
- [1] https://www.drugpatentwatch.com/patent/